CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced that it has granted equity awards to 19 new non-executive employees as part of its 2025 Inducement Plan. The awards, approved by the company’s independent Compensation Committee, were made in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity inducements were provided as material incentives for employees joining the company. In total, the new hires received options to purchase 889 shares of Madrigal common stock and 8,581 time-based restricted stock units (RSUs).
The stock options carry an exercise price of $433.45 per share, equal to the company’s closing stock price on October 15, 2025 — the grant date. The options will vest 25% after one year, with the remaining 75% vesting in equal quarterly installments over the next three years. All RSUs will vest in four equal annual installments, subject to continued employment on each vesting date.
Madrigal Pharmaceuticals is a biopharmaceutical company specializing in therapies for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease with limited treatment options. The company’s lead product, Rezdiffra (resmetirom), is the first and only medication approved by both the U.S. Food and Drug Administration and the European Commission for treating MASH with moderate to advanced fibrosis (F2 to F3).
Madrigal is currently conducting a Phase 3 outcomes trial evaluating Rezdiffra for compensated MASH cirrhosis (F4c), as it continues to expand its clinical and commercial footprint in the growing liver disease therapeutics market.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.